Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft

doi:10.1016/j.ijpddr.2019.06.003

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

Diana Caridha, Brian Vesely, Katrien van Bocxlaer, Byron Arana, Charles E Mowbray, Sima Rafati, Silvia Uliana, Rosa Reguera, Mara Kreishman-Deitrick, Richard Sciotti, Pierre Buffet, Simon L Croft

Research output: Contribution to journal › Review article › peer-review

Abstract

Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles.

Original language	English
Pages (from-to)	106-117
Number of pages	12
Journal	International journal for parasitology. Drugs and drug resistance
Volume	11
DOIs	https://doi.org/10.1016/j.ijpddr.2019.06.003
Publication status	Published - Dec 2019

Bibliographical note

Keywords

Animals
Clinical Trials as Topic
Disease Models, Animal
Drug Discovery/methods
Drug Evaluation, Preclinical
Humans
Leishmania/drug effects
Leishmaniasis, Cutaneous/drug therapy
Mice

Access to Document

10.1016/j.ijpddr.2019.06.003

Cite this

Caridha, D., Vesely, B., van Bocxlaer, K., Arana, B., Mowbray, C. E., Rafati, S., Uliana, S., Reguera, R., Kreishman-Deitrick, M., Sciotti, R., Buffet, P., & Croft, S. L. (2019). Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. International journal for parasitology. Drugs and drug resistance, 11, 106-117. https://doi.org/10.1016/j.ijpddr.2019.06.003

@article{c3967212a15f468bb84bb4d9ed6cf91f,

title = "Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis",

abstract = "Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles.",

keywords = "Animals, Clinical Trials as Topic, Disease Models, Animal, Drug Discovery/methods, Drug Evaluation, Preclinical, Humans, Leishmania/drug effects, Leishmaniasis, Cutaneous/drug therapy, Mice",

author = "Diana Caridha and Brian Vesely and {van Bocxlaer}, Katrien and Byron Arana and Mowbray, {Charles E} and Sima Rafati and Silvia Uliana and Rosa Reguera and Mara Kreishman-Deitrick and Richard Sciotti and Pierre Buffet and Croft, {Simon L}",

year = "2019",

month = dec,

doi = "10.1016/j.ijpddr.2019.06.003",

language = "English",

volume = "11",

pages = "106--117",

journal = "International journal for parasitology. Drugs and drug resistance",

issn = "2211-3207",

publisher = "Elsevier Ltd.",

}

Caridha, D, Vesely, B, van Bocxlaer, K, Arana, B, Mowbray, CE, Rafati, S, Uliana, S, Reguera, R, Kreishman-Deitrick, M, Sciotti, R, Buffet, P & Croft, SL 2019, 'Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis', International journal for parasitology. Drugs and drug resistance, vol. 11, pp. 106-117. https://doi.org/10.1016/j.ijpddr.2019.06.003

TY - JOUR

T1 - Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

AU - Caridha, Diana

AU - Vesely, Brian

AU - van Bocxlaer, Katrien

AU - Arana, Byron

AU - Mowbray, Charles E

AU - Rafati, Sima

AU - Uliana, Silvia

AU - Reguera, Rosa

AU - Kreishman-Deitrick, Mara

AU - Sciotti, Richard

AU - Buffet, Pierre

AU - Croft, Simon L

PY - 2019/12

Y1 - 2019/12

N2 - Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles.

AB - Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles.

KW - Animals

KW - Clinical Trials as Topic

KW - Disease Models, Animal

KW - Drug Discovery/methods

KW - Drug Evaluation, Preclinical

KW - Humans

KW - Leishmania/drug effects

KW - Leishmaniasis, Cutaneous/drug therapy

KW - Mice

U2 - 10.1016/j.ijpddr.2019.06.003

DO - 10.1016/j.ijpddr.2019.06.003

M3 - Review article

C2 - 31320296

SN - 2211-3207

VL - 11

SP - 106

EP - 117

JO - International journal for parasitology. Drugs and drug resistance

JF - International journal for parasitology. Drugs and drug resistance

ER -